Tranexamic Acid tablets recalled due to failed specification testing
AVKARE LLC is recalling Tranexamic Acid USP 650mg tablets nationwide due to failed quality control specifications for conductivity. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This FDA Class III recall involves a manufacturing specification failure with no reported illnesses or injuries. FDA Class III recalls are typically scored 1 or 2; the failed purity and degradation specifications merits classification as Moderate rather than Low.
Plain-English summary
AVKARE LLC is recalling Tranexamic Acid USP 650 mg tablets nationwide. The recall affects 592 cartons with Lot 44286 (expiration February 2025) distributed throughout the United States. The affected product is identified by NDC 50268-772-13.
The product failed specification testing for conductivity, which is a quality control measure for pharmaceutical purity and degradation. Testing results were out of specification, indicating the product does not meet published manufacturing standards.
No illnesses or injuries have been reported. Consumers who have obtained this product should stop using it and contact their healthcare provider or pharmacist for guidance.
The recalled product
- Product
- TRANEXAMIC ACID (TRANEXAMIC ACID)
- Brand
- TRANEXAMIC ACID
- Manufacturer
- AVKARE LLC
- Category
- Drug — Prescription Tablet
- Hazard
- Affected units
- 592
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 44286 Exp. 02/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TRANEXAMIC ACID
- ModerateTranexamic Acid Tablets Recalled for Failed Manufacturing Specifications
FDA (Drugs) · 2023-06-21
- LowTranexamic Acid Injection Recalled for Metal Particulate Matter
FDA (Drugs) · 2022-10-12
- CriticalMylan Recalls Tranexamic Acid Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
Same manufacturer · AVKARE LLC
See all →- HighOTC Topical Cream Cartons May Contain Mislabeled Prescription Toothpaste
FDA (Drugs) · 2023-09-13
- ModeratePrescription Dental Toothpaste Recalled Due to Incorrect Carton Labeling
FDA (Drugs) · 2023-09-13
- HighGlycopyrrolate 1 mg Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-04
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08